Change of Nominated Adviser

RNS Number : 8883K

Hutchison China Meditech Limited

28 August 2012

 



Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Change of Nominated Adviser

London: Tuesday, 28 August 2012: Chi-Med today announces that it has appointed Panmure Gordon (UK) Limited as its nominated adviser with effect from 28 August 2012.  This role is in addition to its existing role as joint corporate broker to Chi-Med, alongside UBS Limited.

The directors of Chi-Med would like to express their thanks to Lazard & Co., Limited for its advice and support over the years.

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone:      [phone]
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone:      [phone] Mobile:             [phone] Mobile:             [phone]
Panmure Gordon (UK) Limited Richard Gray Andrew Potts Grishma Patel	Telephone:      [phone]

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006.  It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.

 

END

 

 

APPMMGZRGRRGZZM